Laboratory of Mammalian Model Organisms, Institute of Bioorganic Chemistry Polish Academy of Sciences, Noskowskiego 12/14, 61-704 Poznan, Poland.
Department of Molecular Neurooncology, Institute of Bioorganic Chemistry Polish Academy of Sciences, Noskowskiego 12/14, 61-704 Poznan, Poland.
Int J Mol Sci. 2023 Feb 24;24(5):4477. doi: 10.3390/ijms24054477.
The human intestinal microbiota is a diverse and dynamic microenvironment that forms a complex, bi-directional relationship with the host. The microbiome takes part in the digestion of food and the generation of crucial nutrients such as short chain fatty acids (SCFA), but is also impacts the host's metabolism, immune system, and even brain functions. Due to its indispensable role, microbiota has been implicated in both the maintenance of health and the pathogenesis of many diseases. Dysbiosis in the gut microbiota has already been implicated in many neurodegenerative diseases such as Parkinson's disease (PD) and Alzheimer's disease (AD). However, not much is known about the microbiome composition and its interactions in Huntington's disease (HD). This dominantly heritable, incurable neurodegenerative disease is caused by the expansion of CAG trinucleotide repeats in the huntingtin gene (). As a result, toxic RNA and mutant protein (mHTT), rich in polyglutamine (polyQ), accumulate particularly in the brain, leading to its impaired functions. Interestingly, recent studies indicated that mHTT is also widely expressed in the intestines and could possibly interact with the microbiota, affecting the progression of HD. Several studies have aimed so far to screen the microbiota composition in mouse models of HD and find out whether observed microbiome dysbiosis could affect the functions of the HD brain. This review summarizes ongoing research in the HD field and highlights the essential role of the intestine-brain axis in HD pathogenesis and progression. The review also puts a strong emphasis on indicating microbiome composition as a future target in the urgently needed therapy for this still incurable disease.
人类肠道微生物群是一个多样化和动态的微环境,与宿主形成复杂的双向关系。微生物组参与食物消化和关键营养素的产生,如短链脂肪酸(SCFA),但也影响宿主的新陈代谢、免疫系统,甚至大脑功能。由于其不可或缺的作用,微生物群与许多疾病的发病机制和维持健康都有关联。肠道微生物群的失调已经与许多神经退行性疾病有关,如帕金森病(PD)和阿尔茨海默病(AD)。然而,对于亨廷顿病(HD)的微生物组组成及其相互作用,我们知之甚少。这种主要遗传性、不可治愈的神经退行性疾病是由亨廷顿基因()中 CAG 三核苷酸重复扩展引起的。结果,有毒的 RNA 和突变蛋白(mHTT),富含聚谷氨酰胺(polyQ),在大脑中特别积累,导致其功能受损。有趣的是,最近的研究表明,mHTT 也广泛表达在肠道中,并且可能与微生物群相互作用,影响 HD 的进展。迄今为止,已有几项研究旨在筛选 HD 小鼠模型中的微生物组组成,并确定观察到的微生物群失调是否会影响 HD 大脑的功能。这篇综述总结了 HD 领域的正在进行的研究,并强调了肠-脑轴在 HD 发病机制和进展中的重要作用。该综述还强烈强调了微生物组组成作为这种仍然无法治愈的疾病迫切需要的治疗方法的未来目标。